VERA Stock Summary and Trading Ideas (Vera Therapeutics - Class A | NASDAQ:VERA)

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.

As of October 26, 2026, VERA stock price climbed to $28.02 with 464,762 million shares trading.

VERA has a beta of 0.95, meaning it tends to be less sensitive to market movements. VERA has a correlation of 0.04 to the broad based SPY ETF.

VERA has a market cap of $2.01 billion. This is considered a Mid Cap stock.

In the last 3 years, VERA traded as high as $56.05 and as low as $9.33.

The top ETF exchange traded funds that VERA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

VERA has underperformed the market in the last year with a price return of -0.6% while the SPY ETF gained +15.2%. VERA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.9% and -6.2%, respectively, while the SPY returned +4.0% and -1.6%, respectively.

VERA support price is $26.96 and resistance is $29.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.